Long-term Strategies for Peptic Ulcer

References

• Periston J AG, Wormsley K G. Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3–29
   PubMed Web of Science ®Google Scholar
• Lane M R, Lee S P. Recurrence of duodenal ulcer after medical treatment. Lancet 1988; i: 1147–9
   Google Scholar
• Graham D Y, Lew G M, Klein P D, et al. Effects of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized controlled study. Ann Intern Med 1992; 116: 705–8
   PubMed Web of Science ®Google Scholar
• Graham D Y, Lew G M, Malahy H M, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493–6
   PubMed Web of Science ®Google Scholar
• Hansky J, Korman M G. Long-term cimetidine in duodenal ulcer. Dig Dis Sci 1979; 24: 465–7
   PubMed Web of Science ®Google Scholar
• Bardhan K D, Hinchcliffe R FC, Bose K, et al. Six years of continuous cimetidine treatment in peptic ulcer disease, 'efficacy and safety'. Aliment Pharmacol Ther 1988; 2: 394–405
   Web of Science ®Google Scholar
• Penston J G, Wormsley K G. Efficacy and safety of long-term maintenance therapy of duodenal ulcers. Scand J Gastroenterol 1989; 24: 1145–52
   PubMed Web of Science ®Google Scholar
• Pounder R E. Maintenance treatment: who should be treated and for how long?. Maintenance treatment, a strategy for the management of peptic ulcer disease. The Medicine Group (UK) Ltd, Oxford 1988; 14–15
   Google Scholar
• Korman M G, Hetzel D J, Hansky J, et al. Relapse rate of duodenal ulcer after cessation of long-term cimetidine treatment. Dig Dis Sci 1980; 25: 88–91
   PubMed Web of Science ®Google Scholar
• McLean A J, Byrne A J, Harrison P M, et al. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust NZ J Med 1985; 15: 367–74
   PubMedGoogle Scholar
• Chiverton S G, Hunt R H. Initial therapy and relapse of duodenal ulcer: possible acid secretory mechanisms. Gastroenterology 1989; 6: 632–9, Suppl
   Google Scholar
• Marks I N, Wright J P, Lucke W, et al. Relapse rate after initial ulcer healing with sucralfate and cimetidine. Scand J Gastroenterol 1982; 17: 429–32
   PubMed Web of Science ®Google Scholar
• Domschke S, Domschke W. Longer relapse-free period after sucralfate than after H2 treatment of duodenal and gastric ulcers. Am J Med 1991; 1(Suppl 2A)74S–84S
   Google Scholar
• Walan A, Porro Bianchi, Hentschel E, Bardhan K D, Delattre M. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397–405
   PubMed Web of Science ®Google Scholar
• Susi D, Janetti G, Di Pietro A M. Long-term therapy of peptic ulcer: our experience with ranitidine after 4 years. Ital J Gastroenterol 1987; 19: 698
   Google Scholar
• Penston J G, Wormsley K G. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmcol Ther 1992; 6: 629–45
   PubMed Web of Science ®Google Scholar
• Gudmund-Hoyer E, Jensen K B, Krag E, et al. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1978; 1: 1095–7
   PubMedGoogle Scholar
• Salera M, Taroni F, Miglioli M, et al. Long-term effects and after-effects of cimetidine in duodenal ulcer patients. Ital J Gastroenterol 1979; 11: 49–52
   Google Scholar
• Korman M. Concepts and controversy in gastroenterology. Case 1: Even simple ulcers can become tricky. Scand J Gastroenterol 1987; 22(Suppl 132)9–13
   Google Scholar
• Penston J G, Dixon J S, Boyd E JS, Wormsley K G. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther 1993; 7: 258–65
   Web of Science ®Google Scholar
• Catford J C, Simpson R J. Confidential enquiry into deaths from peptic ulcer. Health Trends 1986; 18: 37–40
   Google Scholar
• Pulvertaft C N. Incidence and natural history of gastric and duodenal ulcer. Postgrad Med J 1968; 44: 597–602
   PubMed Web of Science ®Google Scholar
• Sommerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; i: 462–4
   Google Scholar
• Faulkner G, Pritchard P, Somerville K, Langman M JS. Aspirin and bleeding peptic ulcers in the elderly. Br Med J 1988; 297: 1311–3
   PubMed Web of Science ®Google Scholar
• Korman M G, Hansky J, Eaves E R, et al. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871–4
   PubMed Web of Science ®Google Scholar
• Das A F, Freston J W, Jacobs J, Fox N A, et al. An evaluation of safety in 37,252 patients treated with cimetidine or ranitidine. Int Med 1990; 11: 3–14
   Google Scholar
• Penston J G. Medical events occurring in patients with duodenal ulcer disease during maintenance treatment with ranitidine. Scand J Gastroenterol 1990; 25(Suppl 177)87–97
   Google Scholar
• Mignon M, Ruszniewski P, Pappo M, Alberola B, Georges D. et Groupe d'Etude de la Maladie Ulcéreuse Duodénale (GEMUD). Traitement des poussées ou traitement préventif des réidives dans la maladie ulcéreuse duodénale?. Gastroenterol Clin Biol 1990; 14: 732–8
   PubMedGoogle Scholar
• Van Deventer G M, Osterhaus J T. Pharmaco-economic benefits of ranitidine maintenance therapy. A retrospective analysis of a clinical trial. J Clin Res Pharmacoepidemiol 1992; 6: 29–37
   Google Scholar
• Pym B, Sandstad J, Seville P, et al. Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology 1990; 99: 27–35
   PubMed Web of Science ®Google Scholar
• Bardhan K D. Intermittent treatment of duodenal ulcer with cimetidine. Br Med J 1980; 281: 20–2
   PubMedGoogle Scholar
• Hetzel D J, Hecker R, Shearman D JC. Long-term treatment of duodenal ulcer with cimetidine. intermittent or continuous therapy?. Med J Aust 1980; 2: 612–4
   PubMed Web of Science ®Google Scholar
• Gustavsson S, Holmberg L, Nyren O, Ohrvall U, Wells L. Risk of serious complications in patients with duodenal or prepyloric ulcers. Gastroenterology 1990; 98: A54, (Abstract)
   Google Scholar
• Pounder R E, Festen H, Korman M. The long-term management of duodenal ulceration using an H2-antagonist: symptomatic self-care compared with maintenance treatment. Aliment Pharmacol Ther 1992; 6: 315–25
   PubMed Web of Science ®Google Scholar
• Crowe J P, Wilkinson S P, Bate C M, et al. Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Aliment Pharmacol Ther 1989; 3: 83–91
   PubMed Web of Science ®Google Scholar
• Tytgat G NJ, Lamers C BHW, Hameetman W, Jansen J MBJ, Wilson J A. Omeprazole in peptic ulcer resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther 1987; 1: 31–8
   PubMedGoogle Scholar
• Lauritsen K, Andersen B N, Laursen L S, et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Gastroenterology 1991; 100: 663–9
   PubMed Web of Science ®Google Scholar
• Lam S K. Clinical efficacy of sucralfate in the short term treatment of peptic ulcer. Progr Med 1989; 9: 787–801
   Google Scholar
• Bolin T O. Sucralfate maintenance therapy in duodenal ulcer disease. A review. Am J Med 1989; 86(Suppl 6A)148–51
   PubMed Web of Science ®Google Scholar